AZD5438 in Patients With Advanced Solid Malignancies

Phase 1

Completed

• Conditions: Neoplasms

• Registration Number: NCT00088790
• Lead Sponsor: AstraZeneca

Brief Summary

Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-07
• Study First Submitted: 2004-08-04
• Study First Submitted QC: 2004-08-04
• Study First Posted: 2004-08-05
• Primary Completion: 2005-12
• Study Completion: 2005-12
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-25
• Last Update Posted: 2011-01-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Advanced solid malignancy
• Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria

• Radiotherapy within 3 weeks of the start of treatment
• Investigational product within the last 3 weeks
• Systemic cytotoxic anti-cancer therapy within the last 3 weeks
• Any significant clinical disorder that makes it undesirable for the patient to participate

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇺🇸 New York City, New York, United States